Symbols / BCTX Stock $3.73 -4.60% BriaCell Therapeutics Corp.
BCTX (Stock) Chart
About
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Stock Fundamentals
Scroll to Statements| Market Cap | 27.04M | Enterprise Value | -2.26M | Income | -29.64M | Sales | — | Book/sh | 4.26 | Cash/sh | 4.12 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -9.56 |
| PEG | — | P/S | — | P/B | 0.87 | P/C | — | EV/EBITDA | 0.07 | EV/Sales | — |
| Quick Ratio | 9.39 | Current Ratio | 10.10 | Debt/Eq | — | LT Debt/Eq | — | EPS (ttm) | -14.42 | EPS next Y | -0.39 |
| EPS Growth | — | Revenue Growth | — | Earnings | 2025-10-15 | ROA | -89.44% | ROE | -179.21% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 7.25M | Shs Float | 6.41M | Short Float | 3.90% |
| Short Ratio | 1.19 | Short Interest | — | 52W High | 98.20 | 52W Low | 3.60 | Beta | 1.63 | Avg Volume | 256.89K |
| Volume | 275.33K | Target Price | — | Recom | None | Prev Close | $3.91 | Price | $3.73 | Change | -4.60% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$3.73
Latest analyst target
3. DCF / Fair value
$-50.88
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$3.73
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-08-27 | main | HC Wainwright & Co. | Buy → Buy | $40 |
| 2025-04-22 | reit | HC Wainwright & Co. | Buy → Buy | $32 |
| 2025-02-03 | main | HC Wainwright & Co. | Buy → Buy | $32 |
| 2024-12-12 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-12-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-10-03 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-19 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2024-09-11 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-06-04 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
| 2024-05-24 | reit | HC Wainwright & Co. | Buy → Buy | $18 |
- Late-stage breast cancer patients preserved quality of life in trial - Stock Titan Mon, 20 Apr 2026 11
- BCTX (BriaCell Therapeutics Corp.) posts narrower than expected Q1 2026 loss, shares rise 1.76% today. - Hot Community Stocks - Cổng thông tin điện tử Tỉnh Sơn La hu, 23 Apr 2026 10
- BriaCell Shares Slide 22% After Announcing Dilutive Public Offering - MSN hu, 23 Apr 2026 09
- BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting - GuruFocus ue, 21 Apr 2026 13
- What should I do with BriaCell (BCTX) stock today (Pressure Mounts) 2026-04-20 - Retail Trader Ideas - Cổng thông tin điện tử tỉnh Lào Cai Mon, 20 Apr 2026 15
- Why Did BCTX Stock Surge 50% Today? - Stocktwits hu, 05 Mar 2026 08
- All You Need to Know About BRIACELL THERAP (BCTX) Rating Upgrade to Buy - Yahoo Finance Fri, 12 Sep 2025 07
- BriaCell says lab immune cells kept killing tumor cells in repeat tests - Stock Titan ue, 21 Apr 2026 11
- BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting - GuruFocus Mon, 20 Apr 2026 16
- MSN Money - MSN Wed, 22 Apr 2026 23
- What is happening with BriaCell (BCTX) Stock right now | BCTX Q4 Earnings: Beats Estimates by $2.31 - Financial Update - UBND thành phố Hải Phòng Mon, 13 Apr 2026 07
- Is BriaCell (BCTX) Stock Priced Correctly | Price at $4.32, Up 5.37% - Technical Analysis - Cổng thông tin điện tử Tỉnh Sơn La Mon, 06 Apr 2026 07
- BCTX SEC Filings - Briacell Therapeutics Corp 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 01 Apr 2026 23
- BriaCell (Nasdaq: BCTX) targets 1H2026 topline data in Phase 3 MBC trial under Fast Track - Stock Titan ue, 09 Dec 2025 08
- Why one metastatic breast cancer trial is a key one to watch in 2026 - Stock Titan hu, 18 Dec 2025 08
Insider Transactions
Financials
Statement View
| Line Item | Trend | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
33.33
+43.22%
|
23.27
+52.25%
|
15.29
+119.23%
|
6.97
|
| Research And Development |
|
27.18
+77.21%
|
15.34
+91.19%
|
8.02
+296.93%
|
2.02
|
| Selling General And Administration |
|
6.15
-22.47%
|
7.94
+9.19%
|
7.27
+46.67%
|
4.96
|
| General And Administrative Expense |
|
6.15
-22.47%
|
7.94
+9.19%
|
7.27
+46.67%
|
4.96
|
| Salaries And Wages |
|
—
|
—
|
—
|
2.15
|
| Other Gand A |
|
6.15
-22.47%
|
7.94
+9.19%
|
7.27
+46.67%
|
4.96
|
| Other Operating Expenses |
|
—
|
—
|
-0.00
+8.21%
|
-0.00
|
| Total Expenses |
|
33.33
+43.22%
|
23.27
+52.25%
|
15.29
+119.23%
|
6.97
|
| Operating Income |
|
-33.33
-43.22%
|
-23.27
-52.25%
|
-15.29
-119.23%
|
-6.97
|
| Total Operating Income As Reported |
|
-33.33
-43.22%
|
-23.27
-52.22%
|
-15.29
-119.24%
|
-6.97
|
| EBITDA |
|
-4.85
+79.16%
|
-23.26
+13.29%
|
-26.82
-95.47%
|
-13.72
|
| Normalized EBITDA |
|
-33.06
-30.51%
|
-25.34
-67.41%
|
-15.13
-117.63%
|
-6.95
|
| Reconciled Depreciation |
|
0.08
+449.39%
|
0.02
-0.01%
|
0.02
+0.10%
|
0.02
|
| EBIT |
|
-4.93
+78.81%
|
-23.27
+13.29%
|
-26.84
-95.36%
|
-13.74
|
| Total Unusual Items |
|
28.22
+1257.46%
|
2.08
+117.78%
|
-11.69
-72.70%
|
-6.77
|
| Total Unusual Items Excluding Goodwill |
|
28.22
+1257.46%
|
2.08
+117.78%
|
-11.69
-72.70%
|
-6.77
|
| Special Income Charges |
|
—
|
—
|
0.00
+100.00%
|
-0.14
|
| Other Special Charges |
|
—
|
—
|
—
|
0.14
|
| Net Income |
|
-4.79
+76.40%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Pretax Income |
|
-4.93
+75.71%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Net Non Operating Interest Income Expense |
|
0.29
-67.68%
|
0.89
+556.50%
|
0.14
+280.03%
|
-0.08
|
| Interest Expense Non Operating |
|
—
|
0.00
-100.00%
|
0.00
-98.75%
|
0.08
|
| Net Interest Income |
|
0.29
-67.68%
|
0.89
+556.50%
|
0.14
+280.03%
|
-0.08
|
| Interest Expense |
|
—
|
0.00
-100.00%
|
0.00
-98.75%
|
0.08
|
| Interest Income Non Operating |
|
0.29
-67.68%
|
0.89
+551.80%
|
0.14
+4242.05%
|
0.00
|
| Interest Income |
|
0.29
-67.68%
|
0.89
+551.80%
|
0.14
+4242.05%
|
0.00
|
| Other Income Expense |
|
28.11
+1252.34%
|
2.08
+117.78%
|
-11.69
-72.70%
|
-6.77
|
| Gain On Sale Of Security |
|
28.22
+1257.46%
|
2.08
+117.78%
|
-11.69
-76.39%
|
-6.63
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-4.93
+75.71%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Net Income From Continuing Operation Net Minority Interest |
|
-4.79
+76.40%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Net Income From Continuing And Discontinued Operation |
|
-4.79
+76.40%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Net Income Continuous Operations |
|
-4.93
+75.71%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Minority Interests |
|
0.14
|
0.00
|
—
|
—
|
| Normalized Income |
|
-33.01
-47.48%
|
-22.38
-47.73%
|
-15.15
-114.96%
|
-7.05
|
| Net Income Common Stockholders |
|
-4.79
+76.40%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Diluted EPS |
|
-43.68
+77.60%
|
-195.00
+24.86%
|
-259.50
|
—
|
| Basic EPS |
|
-43.68
+77.60%
|
-195.00
+24.86%
|
-259.50
|
—
|
| Basic Average Shares |
|
0.11
+5.35%
|
0.10
+0.81%
|
0.10
|
—
|
| Diluted Average Shares |
|
0.11
+5.35%
|
0.10
+0.81%
|
0.10
|
—
|
| Diluted NI Availto Com Stockholders |
|
-4.79
+76.40%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Amortization |
|
—
|
—
|
—
|
0.02
|
| Amortization Of Intangibles Income Statement |
|
—
|
—
|
—
|
0.02
|
| Depreciation Amortization Depletion Income Statement |
|
—
|
—
|
—
|
0.02
|
| Depreciation And Amortization In Income Statement |
|
—
|
—
|
—
|
0.02
|
| Depreciation Income Statement |
|
—
|
—
|
—
|
0.02
|
| Earnings From Equity Interest |
|
-0.11
|
0.00
|
—
|
—
|
| Insurance And Claims |
|
—
|
—
|
—
|
0.32
|
| Rent And Landing Fees |
|
—
|
—
|
—
|
0.01
|
| Rent Expense Supplemental |
|
—
|
—
|
—
|
0.01
|
| Total Other Finance Cost |
|
—
|
—
|
11.66
+162.05%
|
4.45
|
| Line Item | Trend | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Total Assets |
|
5.87
-78.38%
|
27.16
-36.20%
|
42.58
-26.65%
|
58.04
|
| Current Assets |
|
3.65
-86.44%
|
26.95
-36.36%
|
42.35
-26.73%
|
57.80
|
| Cash Cash Equivalents And Short Term Investments |
|
0.86
-95.94%
|
21.25
-48.22%
|
41.04
-28.33%
|
57.27
|
| Cash And Cash Equivalents |
|
0.86
-95.94%
|
21.25
-48.22%
|
41.04
-28.33%
|
57.27
|
| Cash Financial |
|
—
|
—
|
—
|
57.27
|
| Receivables |
|
1.37
+90.74%
|
0.72
+2877.81%
|
0.02
+91.69%
|
0.01
|
| Accounts Receivable |
|
—
|
0.02
-21.70%
|
0.02
+91.69%
|
0.01
|
| Other Receivables |
|
1.37
+90.74%
|
0.72
|
—
|
—
|
| Prepaid Assets |
|
1.42
-71.43%
|
4.98
+288.75%
|
1.28
+147.82%
|
0.52
|
| Total Non Current Assets |
|
2.22
+931.48%
|
0.22
-6.63%
|
0.23
-6.22%
|
0.25
|
| Net PPE |
|
0.39
|
0.00
|
—
|
—
|
| Gross PPE |
|
0.46
|
0.00
|
—
|
—
|
| Accumulated Depreciation |
|
-0.07
|
0.00
|
—
|
—
|
| Other Properties |
|
0.46
|
—
|
—
|
—
|
| Goodwill And Other Intangible Assets |
|
0.20
-7.10%
|
0.22
-6.63%
|
0.23
-6.22%
|
0.25
|
| Other Intangible Assets |
|
0.20
-7.10%
|
0.22
-6.63%
|
0.23
-6.22%
|
0.25
|
| Investments And Advances |
|
0.42
+20924400.00%
|
0.00
+0.00%
|
0.00
+0.00%
|
0.00
|
| Long Term Equity Investment |
|
0.42
|
0.00
|
—
|
—
|
| Non Current Prepaid Assets |
|
1.21
|
0.00
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
8.56
-72.34%
|
30.94
-4.05%
|
32.25
+6.18%
|
30.37
|
| Current Liabilities |
|
7.46
+314.17%
|
1.80
+91.42%
|
0.94
+69.02%
|
0.56
|
| Payables And Accrued Expenses |
|
7.46
+314.17%
|
1.80
+91.42%
|
0.94
+69.02%
|
0.56
|
| Payables |
|
7.17
+538.12%
|
1.12
+142.56%
|
0.46
+57.00%
|
0.30
|
| Accounts Payable |
|
7.17
+538.12%
|
1.12
+142.56%
|
0.46
+116.37%
|
0.21
|
| Other Payable |
|
—
|
—
|
—
|
0.08
|
| Current Accrued Expenses |
|
0.29
-57.15%
|
0.68
+41.84%
|
0.48
+82.57%
|
0.26
|
| Total Non Current Liabilities Net Minority Interest |
|
1.10
-96.24%
|
29.14
-6.92%
|
31.31
+5.00%
|
29.82
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
—
|
—
|
0.03
|
| Long Term Debt |
|
—
|
—
|
—
|
0.03
|
| Stockholders Equity |
|
-2.38
+36.93%
|
-3.78
-136.57%
|
10.33
-62.67%
|
27.67
|
| Common Stock Equity |
|
-2.38
+36.93%
|
-3.78
-136.57%
|
10.33
-62.67%
|
27.67
|
| Capital Stock |
|
72.17
+3.70%
|
69.59
+6.10%
|
65.59
+19.74%
|
54.77
|
| Common Stock |
|
72.17
+3.70%
|
69.59
+6.10%
|
65.59
+19.74%
|
54.77
|
| Share Issued |
|
0.12
+14.41%
|
0.11
+2.99%
|
0.10
+1.63%
|
0.10
|
| Ordinary Shares Number |
|
0.12
+14.41%
|
0.11
+2.99%
|
0.10
+1.63%
|
0.10
|
| Additional Paid In Capital |
|
—
|
7.42
+41.96%
|
5.23
+140.03%
|
2.18
|
| Retained Earnings |
|
-85.44
-5.94%
|
-80.65
-33.64%
|
-60.35
-107.09%
|
-29.14
|
| Gains Losses Not Affecting Retained Earnings |
|
-0.14
+0.00%
|
-0.14
+0.00%
|
-0.14
+0.00%
|
-0.14
|
| Minority Interest |
|
-0.30
|
0.00
|
—
|
—
|
| Other Equity Adjustments |
|
-0.14
+0.00%
|
-0.14
+0.00%
|
-0.14
+0.00%
|
-0.14
|
| Total Equity Gross Minority Interest |
|
-2.68
+28.92%
|
-3.78
-136.57%
|
10.33
-62.67%
|
27.67
|
| Total Capitalization |
|
-2.38
+36.93%
|
-3.78
-136.57%
|
10.33
-62.71%
|
27.70
|
| Working Capital |
|
-3.81
-115.14%
|
25.15
-39.27%
|
41.41
-27.66%
|
57.24
|
| Invested Capital |
|
-2.38
+36.93%
|
-3.78
-136.57%
|
10.33
-62.71%
|
27.70
|
| Total Debt |
|
—
|
—
|
—
|
0.03
|
| Net Tangible Assets |
|
-2.58
+35.32%
|
-3.99
-139.53%
|
10.10
-63.18%
|
27.43
|
| Tangible Book Value |
|
-2.58
+35.32%
|
-3.99
-139.53%
|
10.10
-63.18%
|
27.43
|
| Derivative Product Liabilities |
|
1.10
-96.24%
|
29.14
-6.92%
|
31.31
+5.09%
|
29.79
|
| Investmentsin Subsidiariesat Cost |
|
0.42
|
0.00
|
—
|
—
|
| Other Equity Interest |
|
11.03
+48.66%
|
7.42
|
—
|
18.37
|
| Line Item | Trend | 2024-07-31 | 2023-07-31 | 2022-07-31 | 2021-07-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-24.13
-1.61%
|
-23.74
-90.20%
|
-12.48
-61.08%
|
-7.75
|
| Cash Flow From Continuing Operating Activities |
|
-24.13
-1.61%
|
-23.74
-90.20%
|
-12.48
-61.08%
|
-7.75
|
| Net Income From Continuing Operations |
|
-4.93
+75.71%
|
-20.30
+24.35%
|
-26.84
-94.26%
|
-13.82
|
| Depreciation Amortization Depletion |
|
0.08
+449.39%
|
0.02
-0.01%
|
0.02
+0.10%
|
0.02
|
| Depreciation |
|
0.07
|
0.00
|
—
|
—
|
| Amortization Cash Flow |
|
0.02
+0.00%
|
0.02
-0.01%
|
0.02
|
—
|
| Depreciation And Amortization |
|
0.08
+449.39%
|
0.02
-0.01%
|
0.02
+0.10%
|
0.02
|
| Amortization Of Intangibles |
|
0.02
+0.00%
|
0.02
-0.01%
|
0.02
|
—
|
| Other Non Cash Items |
|
—
|
—
|
-0.00
-100.13%
|
1.88
|
| Stock Based Compensation |
|
1.80
-17.76%
|
2.19
-28.65%
|
3.07
+56.21%
|
1.97
|
| Operating Gains Losses |
|
-28.14
-1227.46%
|
-2.12
-118.18%
|
11.66
+159.72%
|
4.49
|
| Gain Loss On Investment Securities |
|
-28.24
-1232.49%
|
-2.12
-118.18%
|
11.66
+162.05%
|
4.45
|
| Net Foreign Currency Exchange Gain Loss |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
7.05
+299.70%
|
-3.53
-802.65%
|
-0.39
+82.85%
|
-2.28
|
| Change In Receivables |
|
-0.73
-14107.23%
|
0.01
+145.36%
|
-0.01
-215.98%
|
0.01
|
| Change In Prepaid Assets |
|
2.13
+148.35%
|
-4.40
-475.56%
|
-0.76
-656.61%
|
-0.10
|
| Change In Payables And Accrued Expense |
|
5.66
+557.82%
|
0.86
+123.88%
|
0.38
+117.54%
|
-2.19
|
| Change In Accrued Expense |
|
-0.39
-293.76%
|
0.20
+47.94%
|
0.14
+117.21%
|
-0.79
|
| Change In Payable |
|
6.05
+815.58%
|
0.66
+165.07%
|
0.25
+117.73%
|
-1.41
|
| Change In Account Payable |
|
6.05
+815.58%
|
0.66
+165.07%
|
0.25
+117.73%
|
-1.41
|
| Investing Cash Flow |
|
-0.68
|
0.00
|
—
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.68
|
0.00
|
—
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.46
|
0.00
|
—
|
—
|
| Purchase Of PPE |
|
-0.46
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.46
|
—
|
—
|
—
|
| Net Investment Purchase And Sale |
|
—
|
—
|
—
|
0.00
|
| Net Business Purchase And Sale |
|
-0.23
|
0.00
|
—
|
—
|
| Purchase Of Business |
|
-0.23
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
4.42
+11.75%
|
3.95
+205.65%
|
-3.74
-105.76%
|
65.00
|
| Cash Flow From Continuing Financing Activities |
|
4.42
+11.75%
|
3.95
+205.65%
|
-3.74
-105.76%
|
65.00
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.33
|
| Issuance Of Debt |
|
—
|
—
|
0.00
-100.00%
|
0.22
|
| Repayment Of Debt |
|
—
|
—
|
0.00
+100.00%
|
-0.55
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
0.22
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
-0.31
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
-0.09
|
| Short Term Debt Issuance |
|
—
|
—
|
0.00
-100.00%
|
0.22
|
| Short Term Debt Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.55
|
| Net Short Term Debt Issuance |
|
—
|
—
|
0.00
+100.00%
|
-0.33
|
| Net Common Stock Issuance |
|
4.42
+11.79%
|
3.95
+138.86%
|
-10.17
-119.70%
|
51.62
|
| Common Stock Payments |
|
0.00
+100.00%
|
-0.05
+99.54%
|
-10.17
|
0.00
|
| Repurchase Of Capital Stock |
|
0.00
+100.00%
|
-0.05
+99.54%
|
-10.17
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.00
-100.00%
|
0.00
-99.98%
|
6.51
-52.50%
|
13.71
|
| Net Other Financing Charges |
|
—
|
—
|
-0.08
|
—
|
| Changes In Cash |
|
-20.39
-3.02%
|
-19.79
-21.96%
|
-16.23
-128.35%
|
57.25
|
| Effect Of Exchange Rate Changes |
|
—
|
—
|
—
|
0.00
|
| Beginning Cash Position |
|
21.25
-48.22%
|
41.04
-28.33%
|
57.27
+269412.38%
|
0.02
|
| End Cash Position |
|
0.86
-95.94%
|
21.25
-48.22%
|
41.04
-28.33%
|
57.27
|
| Free Cash Flow |
|
-24.58
-3.53%
|
-23.74
-90.20%
|
-12.48
-61.08%
|
-7.75
|
| Common Stock Issuance |
|
4.42
+10.47%
|
4.00
|
0.00
-100.00%
|
51.62
|
| Earnings Losses From Equity Investments |
|
0.11
|
0.00
|
—
|
—
|
| Issuance Of Capital Stock |
|
4.42
+10.47%
|
4.00
|
0.00
-100.00%
|
51.62
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-03-31 View
- 10-Q2026-03-10 View
- 8-K2026-03-09 View
- 8-K2026-02-20 View
- 8-K2026-01-15 View
- 8-K2025-12-29 View
- 10-Q2025-12-11 View
- 8-K2025-12-01 View
- 10-K2025-10-16 View
- 8-K2025-08-26 View
- 8-K2025-07-16 View
- 8-K2025-06-18 View
- 10-Q2025-06-16 View
- 8-K2025-04-28 View
- 10-Q2025-03-12 View
- 8-K2025-03-12 View
- 8-K2025-02-13 View
- 8-K2025-02-06 View
- 8-K2025-02-05 View
- 8-K2025-01-28 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|